Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Amyloid deposition after cerebral hypoperfusion: evidenced on [(18)F]AV-45 positron emission tomography.

Huang KL, Lin KJ, Ho MY, Chang YJ, Chang CH, Wey SP, Hsieh CJ, Yen TC, Hsiao IT, Lee TH.

J Neurol Sci. 2012 Aug 15;319(1-2):124-9. doi: 10.1016/j.jns.2012.04.014. Epub 2012 May 8.

PMID:
22572706
2.

Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.

Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, Kung MP, Wey SP, Hsieh CJ, Wai YY, Yen TC, Huang CC.

PLoS One. 2013;8(3):e58974. doi: 10.1371/journal.pone.0058974. Epub 2013 Mar 14.

3.

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.

Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A.

Neuroimage. 2008 Jan 15;39(2):619-33. Epub 2007 Sep 21.

PMID:
17962045
4.

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL, Kung HP, Zhang W, Kung MP, Skovronsky D, Dyrks T, Holl G, Krause S, Friebe M, Lehman L, Lindemann S, Dinkelborg LM, Masters CL, Villemagne VL.

Lancet Neurol. 2008 Feb;7(2):129-35. doi: 10.1016/S1474-4422(08)70001-2. Epub 2008 Jan 10.

PMID:
18191617
5.

Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.

Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierron E, Vercouillie J, Vellas B, Eustache F, Guilloteau D.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. doi: 10.1007/s00259-011-2021-8. Epub 2012 Jan 18.

6.

Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.

Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH, Yen TC, Kung MP.

Nucl Med Biol. 2010 May;37(4):497-508. doi: 10.1016/j.nucmedbio.2010.02.003. Epub 2010 Apr 7.

PMID:
20447562
7.

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Brasić JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ.

J Nucl Med. 2010 Jun;51(6):913-20. doi: 10.2967/jnumed.109.069088. Erratum in: J Nucl Med. 2010 Aug;51(8):1327.

8.

Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, Chang CJ, Tseng HJ, Yen TC, Liu CY, Lin KJ.

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):714-22.

PMID:
24233127
9.

Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.

Hsiao IT, Huang CC, Hsieh CJ, Wey SP, Kung MP, Yen TC, Lin KJ.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):908-20. doi: 10.1007/s00259-013-2350-x. Epub 2013 Feb 15.

PMID:
23412134
10.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.

Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11.

PMID:
21747008
11.

Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.

Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brašić JR, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG.

Am J Geriatr Psychiatry. 2013 Mar;21(3):272-8. doi: 10.1016/j.jagp.2012.11.016.

12.

Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging.

Ercoli LM, Small GW, Siddarth P, Kepe V, Huang SC, Miller KJ, Lavretsky H, Bookheimer SY, Barrio JR, Silverman DH.

Int J Geriatr Psychiatry. 2012 Oct;27(10):1017-27. doi: 10.1002/gps.2816. Epub 2012 Mar 1.

13.

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2006 Nov 14;67(9):1575-80. Epub 2006 Sep 13.

PMID:
16971697
14.

Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.

Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, Fonov V, Jia J, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

PLoS One. 2012;7(10):e47905. doi: 10.1371/journal.pone.0047905. Epub 2012 Oct 24.

15.

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S, Meyer PM, Wolf H, Zimmermann T, Reischl J, Rohde B, Gertz HJ, Reininger C, Sabri O.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6.

PMID:
21547601
16.

Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials.

Tryputsen V, DiBernardo A, Samtani M, Novak GP, Narayan VA, Raghavan N; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;43(3):809-21. doi: 10.3233/JAD-131979.

PMID:
25114074
17.

Effects of brain amyloid deposition and reduced glucose metabolism on the default mode of brain function in normal aging.

Kikuchi M, Hirosawa T, Yokokura M, Yagi S, Mori N, Yoshikawa E, Yoshihara Y, Sugihara G, Takebayashi K, Iwata Y, Suzuki K, Nakamura K, Ueki T, Minabe Y, Ouchi Y.

J Neurosci. 2011 Aug 3;31(31):11193-9. doi: 10.1523/JNEUROSCI.2535-11.2011.

18.

A modified method of 3D-SSP analysis for amyloid PET imaging using [¹¹C]BF-227.

Kaneta T, Okamura N, Minoshima S, Furukawa K, Tashiro M, Furumoto S, Iwata R, Fukuda H, Takahashi S, Yanai K, Kudo Y, Arai H.

Ann Nucl Med. 2011 Dec;25(10):732-9. doi: 10.1007/s12149-011-0518-7. Epub 2011 Jul 27.

PMID:
21792587
19.

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC.

J Nucl Med. 2011 Aug;52(8):1210-7. doi: 10.2967/jnumed.111.089730. Epub 2011 Jul 15.

20.

In vivo amyloid imaging with PET in frontotemporal dementia.

Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, Lannfelt L, Långström B, Kilander L.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):100-6. Epub 2007 Sep 11.

PMID:
17846768
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk